공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

치매 치료제 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Dementia Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 928033
페이지 정보 영문
US $ 4,250 ₩ 4,788,000 PDF (Single User License)
US $ 4,750 ₩ 5,352,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,760,000 PDF (Site License)
US $ 7,500 ₩ 8,451,000 PDF (Corporate License)

치매 치료제 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Dementia Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 치매 치료제(Dementia Drugs) 시장 규모는 예측 기간 중 12.1%의 CAGR로 성장할 것으로 예상됩니다. 세계보건기구에 따르면 약 5,000만 명이 치매를 앓고 있으며, 매년 약 1,000만 명에게 치매가 발생하고 있습니다. 치매의 유병률 증가는 시장의 성장을 촉진할 것으로 예상되고 있습니다.

세계의 치매 치료제 시장을 조사했으며, 시장의 개요, 적응증별·약제 분류별·지역별 시장 규모의 추이와 예측, 시장 동향, 시장 성장요인 및 저해요인 분석, 시장 기회, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.


제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장요인
    • 표적 질환의 유병률 증가
    • 새로운 혁신적 기술과 의약품의 도입
    • 정부 자금과 인식 향상 프로그램의 증가
  • 시장 억제요인
    • 질환에 대한 인식의 결여
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 적응증별
    • 루이 소체 치매(Lewy Body Dementia)
    • 파킨슨병 치매
    • 알츠하이머
    • 혈관성 치매
    • 기타
  • 약제 분류별
    • MAO 저해제
    • 글루타민산 저해제
    • 콜린에스테라아제 저해제
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동·아프리카 지역
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Apotex Inc
    • AstraZeneca
    • Auro Pharma
    • Eisai Co., Ltd
    • Eli Lilly and Company
    • Johnson & Johnson
    • Pfizer, Inc.
    • Teva Pharmaceuticals
    • Zydus Pharmaceuticals

제7장 시장 기회 및 향후 전망

KSA 20.06.01

The global dementia drugs market size is expected to grow at a CAGR of 12.1% over the forecast period. Increasing prevalence of target disease and growing geriatric population suffering from these diseases are expected to promote growth of the market. According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth.

The presence and development of pipeline drugs, such as ORAL PF-01913539 by Pfizer, are expected to have a strong positive impact on the growth of this industry. This drug is currently under Phase 3 clinical trial to evaluate its safety and efficacy in the treatment of mild-to-moderate Alzheimer's disease. The result of the clinical trial is expected to be announced in 2020. Other pipeline drugs include BAN2401 by Eisai Inc and Solanezumab by Eli Lilly, which are in Phase 3 of a clinical trial and are going to be launched over the next 6 years.

The increasing government funding for the target disease care, support, and research activities is estimated to fuel the growth of this industry. Various organizations involved in this activity include the National Institute of Health (NIH), Alzheimer's Association, and National Institute on Aging. In 2019, the NIH has spent around USD 387 million on research projects for Alzheimer's Disease Related Dementias (ADRD). These initiatives are anticipated to provide this market with growth opportunities.

Key Market Trends

The Alzheimer's Disease Segment Dominates the Market and is Expected to Continue the Same during the Forecast Period

Alzheimer's disease are expected to grow at a lucrative CAGR during the forecast period. The high prevalence of the diseases is due to the growing geriatric population base coupled with the weak immune system.

According to the World Health Organization, Alzheimer disease is the most common form of dementia and may contribute to 60-70% of cases.

Favorable supportive legislation by government such as National Alzheimer's Project Act (NAPA) offers a historic opportunity to combat Alzheimer's disease and related dementias. This acts aimed at public awareness & engagement and provide supports for people and their families with Alzheimer's disease and related dementias.

Recently, a new proposal known as Alzheimer's Combination Therapy Opportunities was introduced in collaboration of Alzheimer's Association, Alzheimer's Drug Discovery Foundation and Alzheimer's Society UK. This proposal includes a combination of repurposed or repositioned drugs that have the potential to slow down the progression of Alzheimer's and related dementia thereby boosting the segment growth.

The North America Dominates the Market and is Expected to Continue the Same during the Forecast Period

North America dominated with revenue estimated as a result of the presence of sophisticated healthcare facilities and infrastructure in developed countries, such as the U.S. High purchasing power for expensive drugs, reimbursement policies and increasing patient pool are the drivers projected to boost the market demand. As per the National Institute of Neurological Disorders and Stroke, Alzheimer's disease alone, as one dementia disorder, affects more than 5 million people in the U.S. The toll on individuals, caregivers and society is enormous and is expected to increase as the population ages. This aids in supplementing the regional growth.

Asia Pacific is expected to witness the fastest growth over the forecast period owing to the rising disposable income level. In addition, the high prevalence of the target diseases due to the growing geriatric population base coupled with the weak immune system is attributed to the growth of this industry. In developed economies such as Japan, and China there is high potential growth of the market due to the presence of private partnership projects and government initiatives undertaking various control programs. Hence, the market is expected to register a healthy CAGR over the forecast period.

Competitive Landscape

The dementia drugs market is moderately competitive and consist of local as well as global players. The major players include companies such Apotex Inc, AstraZeneca, Auro Pharma, Eisai Co., Ltd, Eli Lilly and Company, Johnson & Johnson, Pfizer, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals.

In an attempt to enhance market position, the key players are now focusing on new product development, collaborations, and mergers & acquisition. For instance, in February 2020, Pfizer collaborated with JANSSEN Alzheimer Immunotherapy Research & Development, LLC for the development of Biological: ACC-001 so as to check safety and tolerability to reduce brain amyloid load as measured by positron emission tomography (PET) scans. This was carried out to expand the treatment options and gain competitive advantage.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Target Disease
    • 4.2.2 Introduction of New and Innovative Technologies and Drugs
    • 4.2.3 Increased Government Funding & Awareness Programs
  • 4.3 Market Restraints
    • 4.3.1 High Failure Rates Of Drugs At Approval Stages
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Indications
    • 5.1.1 Lewy Body Dementia
    • 5.1.2 Parkinsons Disease Dementia
    • 5.1.3 Alzheimer's Disease
    • 5.1.4 Vascular Dementia
    • 5.1.5 Others
  • 5.2 By Drug Class
    • 5.2.1 MAO Inhibitors
    • 5.2.2 Glutamate Inhibitors
    • 5.2.3 Cholinesterase Inhibitors
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Apotex Inc
    • 6.1.2 AstraZeneca
    • 6.1.3 Auro Pharma
    • 6.1.4 Eisai Co., Ltd
    • 6.1.5 Eli Lilly and Company
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Pfizer, Inc.
    • 6.1.8 Teva Pharmaceuticals
    • 6.1.9 Zydus Pharmaceuticals


Back to Top
전화 문의